1. GPCR/G Protein
    Neuronal Signaling
    Autophagy
    Apoptosis
  2. Opioid Receptor
    Autophagy
    Mitophagy
    Ferroptosis
    Apoptosis
  3. Matrine

Matrine  (Synonyms: Matridin-15-one; Vegard; α-Matrine)

Cat. No.: HY-N0164 Purity: ≥98.0%
COA Handling Instructions

Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus that can act as a kappa opioid receptor and u-receptor agonist. Matrine has a variety of pharmacological effects, including anti-cancer, anti-oxidative stress, anti-inflammation and anti-apoptosis effects. Matrine is potential in the research of disease like human non-small cell lung cancer, hepatoma, papillary thyroid cancer and acute kidney injury (AKI).

For research use only. We do not sell to patients.

Matrine Chemical Structure

Matrine Chemical Structure

CAS No. : 519-02-8

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply Now  
Solution
10 mM * 1 mL in DMSO USD 99 In-stock
Estimated Time of Arrival: December 31
Solid + Solvent
10 mM * 1 mL
ready for reconstitution
USD 99 In-stock
Estimated Time of Arrival: December 31
Solid
100 mg USD 90 In-stock
Estimated Time of Arrival: December 31
200 mg USD 160 In-stock
Estimated Time of Arrival: December 31
500 mg USD 320 In-stock
Estimated Time of Arrival: December 31
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 10 publication(s) in Google Scholar

Top Publications Citing Use of Products

    Matrine purchased from MCE. Usage Cited in: Exp Ther Med. 2019 May;17(5):3775-3780.  [Abstract]

    Matrine promotes the nuclear Foxo3a localization and inhibits the levels of cytoplasmic Foxo3a. RC‑4B/C cells are treated with increasing concentrations of matrine for 24 h. The levels of Foxo3 are determined by western blotting analysis. β‑tubulin is used as cytoplasmic marker and lamin B1 is used as nuclear marker in RC‑4B/C cells. The gray values of Foxo3a is shown in histogram in different concentrations of matrine‑treated pituitary cancer cells.

    Matrine purchased from MCE. Usage Cited in: Exp Ther Med. 2019 May;17(5):3775-3780.  [Abstract]

    Matrine increases the expression of pro‑apoptotic proteins in RC‑4B/C cells. RC‑4B/C cells are treated with 0.1, 0.5 and 2.5 mg/ml of matrine for 24 h and the expression of Bim, Bax and Bcl‑2 is determined by western blotting analysis. RC‑4B/C cells treated with 0.1% DMSO are used as negative controls. β‑actin is used as internal reference gene in pituitary cancer cells.

    Matrine purchased from MCE. Usage Cited in: Biomed Pharmacother. 2020 Aug;128:110327.  [Abstract]

    Overexpression of miR-182-5p abolishes the Matrine-induced increase in caspase3 expression and decrease in Bcl-2 expression in vivo. Tumor sections are subjected to IHC staining using an antibody specific for caspase3 and Bcl-2.
    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus that can act as a kappa opioid receptor and u-receptor agonist. Matrine has a variety of pharmacological effects, including anti-cancer, anti-oxidative stress, anti-inflammation and anti-apoptosis effects. Matrine is potential in the research of disease like human non-small cell lung cancer, hepatoma, papillary thyroid cancer and acute kidney injury (AKI)[1][2][3][4][5].

    IC50 & Target

    κ Opioid Receptor/KOR

     

    μ Opioid Receptor/MOR

     

    In Vitro

    Matrine (0-1.5 mg/mL, 24-72 h) inhibits the growth of A549 and SMMC-7721 cells[1].
    Matrine (25 μg/mL, 6 h) suppresses migration of A549 cells[1].
    Matrine (0-1 mg/mL, 48 h) induces apoptosis by reducing the Bcl-2/Bax protein ratios in A549 and SMMC-7721 cells[1].
    Matrine (0-1 mg/mL, 48 h) inhibits miR-182-5p expression and induces the apoptosis of PTC cells[2].
    Matrine (10 μM, 48 h) inhibits cisplatin-induced oxidative injury and inflammation in HK2 cells by reducing ROS level and pro-inflammatory cytokines including IL-1β, IL-6 and TNF-α[4].
    Matrine (10 μM, 48 h) reverses mitochondrial function in cisplatin-induced HK2 cells by activating the SIRT3/OPA1 pathway[4].
    Matrine (0-20 nM, 12 h) promotes HepG2 cell apoptosis by inhibiting mitophagy and PINK1/Parkin pathways[5].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Viability Assay[1]

    Cell Line: A549, SMMC-7721 cells
    Concentration: 0-500 μg/mL for A549 cells, 0-1.5 mg/mL for SMMC-7721 cells
    Incubation Time: 24-72 h
    Result: Inhibited the growth of A549 and SMMC-7721 cells.

    Western Blot Analysis[1]

    Cell Line: A549, SMMC-7721 cells
    Concentration: 100-250 μg/mL for A549 cells, 0.5-1 mg/mL for SMMC-7721 cells
    Incubation Time: 24 h
    Result: Down-regulated the expression of anti-apoptotic protein (Bcl-2) and up-regulated the level of pro-apoptotic protein (bax).

    Immunofluorescence[4]

    Cell Line: HK2 cells
    Concentration: 10 μM
    Incubation Time: 48 h
    Result: Increased SIRT3 expression reduced under cisplatin stimuli.
    In Vivo

    Matrine (Intragastric administration, 40 and 80 mg/kg for 16 consecutive days, xenograft male C57BL/6mice model) inhibits tumors growth and metastasis without affecting the body weight[3].
    Matrine (Intraperitoneal injections, 5 mg/kg, daily for four continuous days) attenuates renal injury and apoptosis in cisplatin-induced AKI mice, as well as reducing inflammatory responses and activating SIRT3/OPA1 axis and rescues renal mitochondrial dysfunction[4].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Xenograft male C57BL/6mice model (LLC cells)[3]
    Dosage: 40 and 80 mg/kg for 16 consecutive days
    Administration: Intragastric administration
    Result: Inhibited tumors growth.
    Decreased the ratio of CD206+/F4/80+, promoted the expression of CD4+ and CD8+ T cells, and inhibited the expression of Th2 in tumor and spleen tissues.
    Animal Model: Cisplatin-induced acute kidney injury (AKI) mice model[4]
    Dosage: 5 mg/kg daily for 4 days
    Administration: Intraperitoneal injections
    Result: Attenuated tubular injury observed in AKI mice, including renal tubular necrosis,formation of tubular casts, cytoplasmic vacuoles and renal infiltrationof inflammatory cells in mice.
    Decreased serum levels of TNF-a and IL-6 and the phosphorylation of NF-κB, activated SIRT3/OPA1 axis and improved mitochondrial function.
    Molecular Weight

    248.36

    Formula

    C15H24N2O

    CAS No.
    SMILES

    O=C1CCC[[email protected]]2([H])[[email protected]@]3([H])CCCN4[[email protected]@]3([H])[[email protected]](CCC4)([H])CN21

    Structure Classification
    Source
    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 50 mg/mL (201.32 mM)

    H2O : 20 mg/mL (80.53 mM; Need ultrasonic)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 4.0264 mL 20.1321 mL 40.2641 mL
    5 mM 0.8053 mL 4.0264 mL 8.0528 mL
    10 mM 0.4026 mL 2.0132 mL 4.0264 mL
    *Please refer to the solubility information to select the appropriate solvent.
    In Vivo:
    • 1.

      Add each solvent one by one:  PBS

      Solubility: 37.5 mg/mL (150.99 mM); Clear solution; Need ultrasonic

    • 2.

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 2.5 mg/mL (10.07 mM); Clear solution

    • 3.

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

      Solubility: ≥ 2.5 mg/mL (10.07 mM); Clear solution

    • 4.

      Add each solvent one by one:  10% DMSO    90% corn oil

      Solubility: ≥ 2.5 mg/mL (10.07 mM); Clear solution

    *All of the co-solvents are available by MCE.
    Purity & Documentation
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Salutation

    Applicant Name *

     

    Email address *

    Phone number *

     

    Organization name *

    Department *

     

    Requested quantity *

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Matrine
    Cat. No.:
    HY-N0164
    Quantity:
    MCE Japan Authorized Agent: